Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

N Engl J Med. 2019 Jun 9. doi: 10.1056/NEJMoa1902226. [Epub ahead of print]

PMID:
31180194
2.

Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D.

Linsley PS, Long SA.

Curr Opin Endocrinol Diabetes Obes. 2019 May 29. doi: 10.1097/MED.0000000000000488. [Epub ahead of print]

PMID:
31157632
3.

Do Skills Acquired from Training with a Wire Navigation Simulator Transfer to a Mock Operating Room Environment?

Long SA, Thomas G, Karam MD, Anderson DD.

Clin Orthop Relat Res. 2019 May 17. doi: 10.1097/CORR.0000000000000799. [Epub ahead of print]

PMID:
31135546
4.

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9.

PMID:
30967424
5.

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.

Habib T, Long SA, Samuels PL, Brahmandam A, Tatum M, Funk A, Hocking AM, Cerosaletti K, Mason MT, Whalen E, Rawlings DJ, Greenbaum C, Buckner JH; Type 1 Diabetes TrialNet Study Group.

Diabetes. 2019 Jun;68(6):1240-1250. doi: 10.2337/db18-1081. Epub 2019 Mar 20.

PMID:
30894366
6.

B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Speake C, Long SA, Dufort MJ.

JCI Insight. 2019 Feb 21;4(4). pii: 126136. doi: 10.1172/jci.insight.126136. eCollection 2019 Feb 21.

7.

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.

Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC; Immune Tolerance Network.

Diabetologia. 2019 Apr;62(4):655-664. doi: 10.1007/s00125-018-4786-9. Epub 2018 Dec 19.

PMID:
30569273
8.

Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.

Schnute ME, Wennerstål M, Alley J, Bengtsson M, Blinn JR, Bolten CW, Braden T, Bonn T, Carlsson B, Caspers N, Chen M, Choi C, Collis LP, Crouse K, Färnegårdh M, Fennell KF, Fish S, Flick AC, Goos-Nilsson A, Gullberg H, Harris PK, Heasley SE, Hegen M, Hromockyj AE, Hu X, Husman B, Janosik T, Jones P, Kaila N, Kallin E, Kauppi B, Kiefer JR, Knafels J, Koehler K, Kruger L, Kurumbail RG, Kyne RE Jr, Li W, Löfstedt J, Long SA, Menard CA, Mente S, Messing D, Meyers MJ, Napierata L, Nöteberg D, Nuhant P, Pelc MJ, Prinsen MJ, Rhönnstad P, Backström-Rydin E, Sandberg J, Sandström M, Shah F, Sjöberg M, Sundell A, Taylor AP, Thorarensen A, Trujillo JI, Trzupek JD, Unwalla R, Vajdos FF, Weinberg RA, Wood DC, Xing L, Zamaratski E, Zapf CW, Zhao Y, Wilhelmsson A, Berstein G.

J Med Chem. 2018 Dec 13;61(23):10415-10439. doi: 10.1021/acs.jmedchem.8b00392. Epub 2018 Sep 9.

PMID:
30130103
9.

Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.

Lord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, Kita M, Buckner JH.

Clin Immunol. 2018 Aug;193:24-32. doi: 10.1016/j.clim.2018.05.006. Epub 2018 May 26.

10.

Cytometry TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome.

Morrell ED, Wiedeman A, Long SA, Gharib SA, West TE, Skerrett SJ, Wurfel MM, Mikacenic C.

JCI Insight. 2018 May 17;3(10). pii: 99281. doi: 10.1172/jci.insight.99281. eCollection 2018 May 17.

11.

The Efficacy of a Novel Surgical Device in Preventing Intraoperative Wound Contamination in an In Vivo Porcine Model.

Suh I, Long SA, Coe J, Koehler J, Fry D, Welton ML.

J Laparoendosc Adv Surg Tech A. 2018 Apr;28(4):445-451. doi: 10.1089/lap.2017.0403. Epub 2017 Aug 28.

PMID:
28846497
12.

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.

Long SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM.

Cell Immunol. 2017 Sep;319:3-9. doi: 10.1016/j.cellimm.2017.07.007. Epub 2017 Aug 18.

13.

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.

Long SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS.

Sci Immunol. 2016 Nov;1(5). pii: eaai7793. doi: 10.1126/sciimmunol.aai7793. Epub 2016 Nov 18.

14.

Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.

Schwedhelm K, Thorpe J, Murray SA, Gavin M, Speake C, Greenbaum C, Cerosaletti K, Buckner J, Long SA.

Clin Immunol. 2017 Aug;181:67-74. doi: 10.1016/j.clim.2017.06.004. Epub 2017 Jun 20.

15.

Radiosurgical Ablation of the Renal Nerve in a Porcine Model: A Minimally Invasive Therapeutic Approach to Treat Refractory Hypertension.

Bhatt N, Long SA, Gardner EA, Tay J, Ladich E, Chamberlain D, Fogarty TJ, Maguire PJ.

Cureus. 2017 Feb 26;9(2):e1055. doi: 10.7759/cureus.1055.

16.

Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.

Hundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, Wight TN, Greenbaum CJ, Cerosaletti K, Buckner JH.

Sci Transl Med. 2016 Sep 14;8(356):356ra119. doi: 10.1126/scitranslmed.aad9943.

17.

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q.

Sci Transl Med. 2015 Nov 25;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134.

18.

The use of desiccation to treat Staphylococcus aureus biofilm-infected wounds.

Park E, Long SA, Seth AK, Geringer M, Xu W, Chavez-Munoz C, Leung K, Hong SJ, Galiano RD, Mustoe TA.

Wound Repair Regen. 2016 Mar;24(2):394-401. doi: 10.1111/wrr.12379. Epub 2015 Dec 10.

PMID:
26519217
19.

Regulatory T Cells Resist Cyclosporine-Induced Cell Death via CD44-Mediated Signaling Pathways.

Ruppert SM, Falk BA, Long SA, Bollyky PL.

Int J Cell Biol. 2015;2015:614297. doi: 10.1155/2015/614297. Epub 2015 Sep 10.

20.

Seeking sunlight: rapid phototactic motility of filamentous mat-forming cyanobacteria optimize photosynthesis and enhance carbon burial in Lake Huron's submerged sinkholes.

Biddanda BA, McMillan AC, Long SA, Snider MJ, Weinke AD.

Front Microbiol. 2015 Sep 7;6:930. doi: 10.3389/fmicb.2015.00930. eCollection 2015.

21.

Association of common polymorphisms in the IL2RA gene with type 1 diabetes: evidence of 32,646 individuals from 10 independent studies.

Tang W, Cui D, Jiang L, Zhao L, Qian W, Long SA, Xu K.

J Cell Mol Med. 2015 Oct;19(10):2481-8. doi: 10.1111/jcmm.12642. Epub 2015 Aug 7.

22.

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR.

J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.

23.

Lethal ovitrap deployment for Aedes aegypti control: potential implications for non-target organisms.

Long SA, Jacups SP, Ritchie SA.

J Vector Ecol. 2015 Jun;40(1):139-45. doi: 10.1111/jvec.12142.

24.

Modeling the impact of restoration efforts on phosphorus loading and transport through Everglades National Park, FL, USA.

Long SA, Tachiev GI, Fennema R, Cook AM, Sukop MC, Miralles-Wilhelm F.

Sci Total Environ. 2015 Jul 1;520:81-95. doi: 10.1016/j.scitotenv.2015.01.094. Epub 2015 Mar 22.

PMID:
25804875
25.

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D.

J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26.

26.

Authors' response: The journey to getting along in Georgia.

Long SA, Bugg K.

J Hum Lact. 2015 Feb;31(1):186. doi: 10.1177/0890334414560410. No abstract available.

PMID:
25583320
27.

Authors' response: A table for two (... Or three, or four).

Long SA, Bugg K.

J Hum Lact. 2015 Feb;31(1):185-6. doi: 10.1177/0890334414560409. No abstract available.

PMID:
25583318
28.

Surveying the knowledge, attitudes, and practices of District of Columbia ACOG members related to breastfeeding.

Sims AM, Long SA, Tender JA, Young MA.

Breastfeed Med. 2015 Jan-Feb;10(1):63-8. doi: 10.1089/bfm.2014.0066. Epub 2014 Nov 12.

PMID:
25389912
29.

Can't we all just get along?

Long SA, Bugg K.

J Hum Lact. 2015 Feb;31(1):29-31. doi: 10.1177/0890334414552526. Epub 2014 Sep 26. No abstract available.

PMID:
25261184
30.

Opioid misuse behaviors in adolescents and young adults in a hematology/oncology setting.

Ehrentraut JH, Kern KD, Long SA, An AQ, Faughnan LG, Anghelescu DL.

J Pediatr Psychol. 2014 Nov-Dec;39(10):1149-60. doi: 10.1093/jpepsy/jsu072. Epub 2014 Sep 14.

31.

Invasion of Wolbachia at the residential block level is associated with local abundance of Stegomyia aegypti, yellow fever mosquito, populations and property attributes.

Hoffmann AA, Goundar AA, Long SA, Johnson PH, Ritchie SA.

Med Vet Entomol. 2014 Aug;28 Suppl 1:90-7. doi: 10.1111/mve.12077.

PMID:
25171611
32.

Renegade homeostatic cytokine responses in T1D: drivers of regulatory/effector T cell imbalance.

Gupta S, Cerosaletti K, Long SA.

Clin Immunol. 2014 Apr;151(2):146-54. doi: 10.1016/j.clim.2014.02.007. Epub 2014 Feb 24. Review.

PMID:
24576418
33.

Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients.

Cerosaletti K, Schneider A, Schwedhelm K, Frank I, Tatum M, Wei S, Whalen E, Greenbaum C, Kita M, Buckner J, Long SA.

PLoS One. 2013 Dec 23;8(12):e83811. doi: 10.1371/journal.pone.0083811. eCollection 2013.

34.

Product-to-parent reversion of trenbolone: unrecognized risks for endocrine disruption.

Qu S, Kolodziej EP, Long SA, Gloer JB, Patterson EV, Baltrusaitis J, Jones GD, Benchetler PV, Cole EA, Kimbrough KC, Tarnoff MD, Cwiertny DM.

Science. 2013 Oct 18;342(6156):347-51. doi: 10.1126/science.1243192. Epub 2013 Sep 26.

35.

Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.

Bollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ.

Clin Exp Immunol. 2013 Jun;172(3):363-74. doi: 10.1111/cei.12064.

36.

Identification and environmental implications of photo-transformation products of trenbolone acetate metabolites.

Kolodziej EP, Qu S, Forsgren KL, Long SA, Gloer JB, Jones GD, Schlenk D, Baltrusaitis J, Cwiertny DM.

Environ Sci Technol. 2013 May 21;47(10):5031-41. doi: 10.1021/es3052069. Epub 2013 May 1.

PMID:
23597146
37.

IL-2 therapy in type 1 diabetes: "Trials" and tribulations.

Long SA, Buckner JH, Greenbaum CJ.

Clin Immunol. 2013 Dec;149(3):324-31. doi: 10.1016/j.clim.2013.02.005. Epub 2013 Feb 22. Review.

PMID:
23499139
38.

The DC breastfeeding-friendly hospital initiative: an evaluation of hospitals' support for breastfeeding in the capital of the United States.

Long SA, Young MA, Tender JA, Dewitty VP, Logan K, Kadeshe M, Ryan C, Haynes SG.

J Hum Lact. 2013 Nov;29(4):465-8. doi: 10.1177/0890334413478834. Epub 2013 Mar 7.

PMID:
23470787
39.

In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling.

Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH.

Sci Transl Med. 2013 Jan 30;5(170):170ra15. doi: 10.1126/scitranslmed.3004970.

40.

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; Diabetes TrialNet and the Immune Tolerance Network.

Diabetes. 2012 Sep;61(9):2340-8. doi: 10.2337/db12-0049. Epub 2012 Jun 20.

41.

Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds.

Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Walker MC, Schweitzer BA, Madsen HM, Tenbrink RE, McDonald J, Smith SE, Foltin S, Beidler D, Thorarensen A.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6538-44. doi: 10.1016/j.bmcl.2011.08.055. Epub 2011 Aug 22.

PMID:
21924614
42.

Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.

Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Schweitzer BA, Wilcox MV, McDonald J, Smith SE, Foltin S, Rumsey J, Yang YS, Walker MC, Kamtekar S, Beidler D, Thorarensen A.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6545-53. doi: 10.1016/j.bmcl.2011.08.048. Epub 2011 Aug 19.

PMID:
21924613
43.

Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells.

Long SA, Rieck M, Tatum M, Bollyky PL, Wu RP, Muller I, Ho JC, Shilling HG, Buckner JH.

J Immunol. 2011 Oct 1;187(7):3511-20. doi: 10.4049/jimmunol.1003880. Epub 2011 Aug 24.

44.

CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game.

Long SA, Buckner JH.

J Immunol. 2011 Sep 1;187(5):2061-6. doi: 10.4049/jimmunol.1003224. Review.

45.

ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors.

Bollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, Teng B, Holt GE, Standifer NE, Braun KR, Xie CF, Samuels PL, Vernon RB, Gebe JA, Wight TN, Nepom GT.

Proc Natl Acad Sci U S A. 2011 May 10;108(19):7938-43. doi: 10.1073/pnas.1017360108. Epub 2011 Apr 25.

46.

An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells.

Long SA, Cerosaletti K, Wan JY, Ho JC, Tatum M, Wei S, Shilling HG, Buckner JH.

Genes Immun. 2011 Mar;12(2):116-25. doi: 10.1038/gene.2010.54. Epub 2010 Dec 23.

47.

Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.

Meyers MJ, Arhancet GB, Hockerman SL, Chen X, Long SA, Mahoney MW, Rico JR, Garland DJ, Blinn JR, Collins JT, Yang S, Huang HC, McGee KF, Wendling JM, Dietz JD, Payne MA, Homer BL, Heron MI, Reitz DB, Hu X.

J Med Chem. 2010 Aug 26;53(16):5979-6002. doi: 10.1021/jm100505n.

PMID:
20672822
48.
49.

Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse.

Bollyky PL, Evanko SP, Wu RP, Potter-Perigo S, Long SA, Kinsella B, Reijonen H, Guebtner K, Teng B, Chan CK, Braun KR, Gebe JA, Nepom GT, Wight TN.

Cell Mol Immunol. 2010 May;7(3):211-20. doi: 10.1038/cmi.2010.9. Epub 2010 Mar 15.

50.

Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.

Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1543-7. doi: 10.1016/j.bmcl.2010.01.078. Epub 2010 Jan 21.

PMID:
20137931

Supplemental Content

Support Center